Tel: +34 918 049 064  ·  info@mecwins.com

Home › Alzheimer’s Innovation

Alzheimer’s Innovation

Advancing ultrasensitive biomarker detection for the diagnosis, prognosis and monitoring of Alzheimer’s disease.

Alzheimer’s Disease Mecwins & AD BRAIN initiative BRAIN members Publications News

mecwins & AD

Precision technology for early detection

Mecwins, as a biotechnological company, is deeply committed to advancing diagnostic tools that contribute to a better understanding of Alzheimer’s disease. Through continuous innovation and research, Mecwins aims to develop high-precision technologies that can improve the detection and monitoring of biomarkers, thus enhancing the capacity for early diagnosis and more effective disease management.

In this context, focusing on fluid biomarkers, the AVAC technology developed by Mecwins provides high robustness and greater sensitivity in measuring the analytes of interest. This advancement could lead to more accurate results, allowing for a clearer definition and study of AD and its progression.

brain initiative

Biomedical Research on Alzheimer’s Innovation Network

Motivated by the critical need to identify biomarkers that can improve the diagnosis, prognosis, and monitoring of Alzheimer’s disease therapies, an innovative collaborative initiative has taken shape. This initiative seeks to advance our understanding of Alzheimer’s, focusing on identifying the most promising biomarkers and developing accurate analytical tools to support early diagnosis, track disease progression, and evaluate therapeutic responses.

This effort has materialized in the BRAIN group (Biomedical Research on Alzheimer’s Innovation Network), a consortium that brings together professionals and institutions dedicated to tackling the complexities of Alzheimer’s disease. Through this coordinated approach, BRAIN brings together diverse expertise and resources, providing a robust foundation for biomarker research that promises to deepen our understanding of Alzheimer’s disease and pave the way for future advancements.

The multicenter and interdisciplinary nature of this collaboration is key to its potential impact. By incorporating a range of perspectives and specialties, this framework fosters the exchange of ideas and the development of comprehensive solutions, allowing for accelerated progress in addressing one of the most challenging neurological diseases of our time.

The BRAIN group, a collaborative initiative founded by Mecwins, brings together professionals from a wide range of disciplines. This multidisciplinary consortium combines the expertise of Mecwins in developing high-precision technologies for biomarker detection with the specialization of Destina Genomica in nucleic acid testing and advanced diagnostic assays. It also benefits from the clinical and research support of Hospital Universitario Ramón y Cajal, recognized for its excellence in healthcare, teaching, and biomedical research, and the academic participation of Universidad Autónoma de Madrid, a leading institution in education and scientific research.

MecwinsDestina GenómicaHospital Universitario Ramón y CajalUniversidad Autónoma de Madrid

brain members

The people driving the initiative

Mecwins

Óscar Ahumada, PhD

Óscar Ahumada, PhD

PhD in Physics and PhD in Natural Sciences with broad expertise in automating optical reading platforms and developing biomedical devices from proof of concept to commercial success. Extensive experience in founding and growing technological companies. CEO of Mecwins for 16 years, focused on commercializing innovative technologies worldwide, and expanding the company’s presence in key markets in Asia, the Americas and Europe.

Virginia Cebrián, PhD

Virginia Cebrián, PhD

PhD in Biochemistry and MSc in Drug Research with more than 10 years of experience in the field of biosensors and nanotechnology with many publications and one patent. Participation in numerous research projects, collaborating with international groups in the development of biosensors. Currently, Head of Bioscience Department at Mecwins S.A. leading the development of biosensors and immunoassays for the ultrasensitive detection of protein biomarkers.

Noemí Marina, PhD

Noemí Marina, PhD

PhD in Biochemistry and Molecular Biology, consolidated expertise through six years of post-doctoral research in the USA and Spain, focusing on innate immunity and the pathogenesis of inflammatory diseases and cancer. Senior Scientist at Biokit Research and Development S.L.U., and currently at Mecwins S.A., leading the development, validation, and manufacturing transfer of diagnostic immunoassays.

Daniel Insua, PhD

Daniel Insua, PhD

PhD in Neuroscience with over 20 years dedicated to Alzheimer’s disease (AD) research in humans and animal models. Extensive expertise in histology, cell culture, antibody production and immunoassays. Researcher at Araclon Biotech S.L., contributing to develop immunotherapies and diagnostic tools for AD. Currently, Senior Scientist at Mecwins S.A., leading the development of biomarker-based immunoassays for the diagnosis, staging and monitoring therapies in AD.

Destina

Juan J. Díaz-Mochón, PhD

Juan J. Díaz-Mochón, PhD

PhD in Pharmacy, scientist and entrepreneur specializing in chemical biology and liquid biopsy. With an academic background spanning Spain, Italy, and the UK, he has authored over 80 scientific papers and co-invented 10 patents. Co-founder and CEO of DESTINA Genomics Ltd. and associate Professor at the University of Granada. Additionally, he is a co-inventor of CRISPNA technology, co-founder of CRISPNA SL and Nanometric SL.

Mavys Tabraue, PhD

Mavys Tabraue, PhD

PhD in Organic and Pharmaceutical Chemistry, research scientist with a strong expertise in applied research, project leadership, and mentorship in both academic and industrial settings. She has significant experience in private research companies, focusing on designing research solutions that lead to valuable intellectual property. Assay Development Manager at DESTINA Genomica S.L., leading interdisciplinary projects and advancing applied research.

Hospital Universitario Ramón y Cajal

Lucía Soletto, PhD.

Lucía Soletto, PhD.

PhD in Biology, MSc in Clinical Trial Monitoring and Pharmaceutical Development and MSc in Genetics and Cell Biology. Currently part of the Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), enrolled, as biomedical research, in the project “Development of a biomedical sensor for the proteins and miRNAs simultaneous detection for diagnosis and prognosis of Alzheimer´s disease”.

Guillermo García, MD.

Guillermo García, MD.

Neurologist at Hospital Universitario Ramón y Cajal, specializing in neurodegenerative diseases, particularly Alzheimer’s. Extensive experience in clinical trials and biomarker research in neurodegenerative diseases, with numerous publications in this field. Currently, also leads the Cognitive and Behavioral Neurology Study Group of the Asociación Madrileña de Neurología and advises the Confederación de Asociaciones de Familiares de Alzheimer (CEAFA).

Universidad Autónoma de Madrid

Diego Lecumberri, MSc

Diego Lecumberri, MSc

Chemistry Degree by the Universidad de Navarra and MSc in Advanced Materials, Nanotechnology and Photonics at the Universidad Autónoma de Madrid. Currently, PhD student at the Universidad Autónoma de Madrid. Doctoral research focused on advanced materials and nanotechnology, with a particular emphasis on developing innovative contrast agents for clinical imaging.

Emma Martín, PhD

Emma Martín, PhD

PhD in Physics of Materials, specializing in materials science. Doctoral research focused on materials for infrared lasers. Postdoctoral research at Concordia University (Canada) centered rare-earth-doped nanoparticle synthesis. Currently Professor at Universidad Autónoma de Madrid, working on the synthesis and application of nanoparticles for biomedical imaging and non-invasive fluorescence-based measurements.

Dirk Ortgies, PhD

Dirk Ortgies, PhD

PhD in Chemistry, specializing in nanomaterials and biomedical imaging. Contributions to luminescent nanoparticle synthesis and their applications in non-invasive diagnostics. Currently, Researcher at Hospital Ramón y Cajal and Assistant Professor at the Universidad Autónoma de Madrid. Recent work in developing nanosensors for detecting hypoxia in ischemic tissues and infrared imaging of myocardial infarction and lung cancer with targeted nanoparticles.

relevant publications

Recent literature

news

Field updates

funded & supported by

Financiado por la Unión Europea — NextGenerationEUCDTIMinisterio de Ciencia, Innovación y Universidades

Programme: Grant CPP2021-008902 funded by MICIU/AEI/ 10.13039/501100011033 and by the “European Union NextGenerationEU/PRTR”.

Project: Desarrollo de un sensor para la detección simultánea de proteínas y microRNAs para el diagnóstico y pronóstico de la enfermedad de Alzheimer.

Acronym: ALZHEIMER-PROmiR-SENSOR